This company has been marked as potentially delisted and may not be actively trading. Amedica (AMDA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock AMDA vs. INFU, NSPR, TMDIF, PETV, HSAQ, RVP, BTCY, GBS, CTCX, and IVFShould you be buying Amedica stock or one of its competitors? The main competitors of Amedica include InfuSystem (INFU), InspireMD (NSPR), Titan Medical (TMDIF), PetVivo (PETV), Health Sciences Acquisitions Co. 2 (HSAQ), Retractable Technologies (RVP), Biotricity (BTCY), GBS (GBS), Carmell (CTCX), and INVO Fertility (IVF). These companies are all part of the "medical" sector. Amedica vs. Its Competitors InfuSystem InspireMD Titan Medical PetVivo Health Sciences Acquisitions Co. 2 Retractable Technologies Biotricity GBS Carmell INVO Fertility InfuSystem (NYSE:INFU) and Amedica (NASDAQ:AMDA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability. Do analysts recommend INFU or AMDA? InfuSystem presently has a consensus price target of $13.50, suggesting a potential upside of 46.98%. Given InfuSystem's stronger consensus rating and higher probable upside, equities research analysts clearly believe InfuSystem is more favorable than Amedica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InfuSystem 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 3 Strong Buy rating(s) 3.40Amedica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to INFU or AMDA? In the previous week, InfuSystem had 1 more articles in the media than Amedica. MarketBeat recorded 1 mentions for InfuSystem and 0 mentions for Amedica. InfuSystem's average media sentiment score of 0.08 beat Amedica's score of 0.00 indicating that InfuSystem is being referred to more favorably in the media. Company Overall Sentiment InfuSystem Neutral Amedica Neutral Do institutionals & insiders hold more shares of INFU or AMDA? 71.1% of InfuSystem shares are held by institutional investors. Comparatively, 3.7% of Amedica shares are held by institutional investors. 11.4% of InfuSystem shares are held by company insiders. Comparatively, 0.9% of Amedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, INFU or AMDA? InfuSystem has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500. Comparatively, Amedica has a beta of -1.24, meaning that its share price is 224% less volatile than the S&P 500. Is INFU or AMDA more profitable? InfuSystem has a net margin of 1.12% compared to Amedica's net margin of -139.62%. InfuSystem's return on equity of 2.78% beat Amedica's return on equity.Company Net Margins Return on Equity Return on Assets InfuSystem1.12% 2.78% 1.41% Amedica -139.62%-148.60%-67.83% Which has stronger valuation and earnings, INFU or AMDA? InfuSystem has higher revenue and earnings than Amedica. Amedica is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInfuSystem$139.89M1.34$870K$0.2339.93Amedica$11.23M4.45-$9.32M-$3.13-1.35 SummaryInfuSystem beats Amedica on 16 of the 17 factors compared between the two stocks. Get Amedica News Delivered to You Automatically Sign up to receive the latest news and ratings for AMDA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMDA vs. The Competition Export to ExcelMetricAmedicaSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.97M$77.53M$6.04B$10.50BDividend YieldN/AN/A5.73%4.80%P/E Ratio-1.359.7684.2027.24Price / Sales4.4539.25510.92196.48Price / CashN/A18.4137.5761.53Price / Book2.3417.1212.226.74Net Income-$9.32M-$27.88M$3.32B$276.59M Amedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMDAAmedicaN/A$4.21+4.0%N/A+27.4%$49.97M$11.23M-1.35N/AGap UpINFUInfuSystem4.4463 of 5 stars$9.27-3.5%$13.50+45.6%+34.0%$189.35M$139.89M154.53410Positive NewsNSPRInspireMD2.9072 of 5 stars$2.37-1.3%$4.50+89.9%-10.2%$98.88M$7.07M-3.1650TMDIFTitan MedicalN/A$0.47+0.7%N/A+1,267.5%$53.38M$17.63M-0.3750Gap UpPETVPetVivoN/A$1.27+1.6%N/A+121.1%$37.19M$1.05M-2.8220HSAQHealth Sciences Acquisitions Co. 2N/A$2.90+6.2%N/A-76.0%$32.52MN/A0.004News CoverageRVPRetractable Technologies2.2515 of 5 stars$0.98-4.9%N/A+19.4%$29.34M$38.16M-1.81240Positive NewsGap DownBTCYBiotricityN/A$0.63-6.0%N/A+154.3%$16.84M$12.06M-0.5840Gap DownGBSGBSN/A$1.13-1.3%N/A+126.1%$16.83MN/A-2.027CTCXCarmellN/A$0.76+7.3%N/A+72.6%$15.89M$32.84K0.0014Gap UpIVFINVO Fertility0.412 of 5 stars$0.75-6.7%N/A-98.3%$3.28M$6.62M-0.0110News Coverage Related Companies and Tools Related Companies InfuSystem Competitors InspireMD Competitors Titan Medical Competitors PetVivo Competitors Health Sciences Acquisitions Co. 2 Competitors Retractable Technologies Competitors Biotricity Competitors GBS Competitors Carmell Competitors INVO Fertility Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMDA) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amedica Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
